Innoviva (INVA) Receivables - Net (2013 - 2026)
Innoviva posted quarterly Receivables - Net of $34.0 million for Q1 2026, up 103.95% year-on-year from $16.7 million in Q1 2025, and down 2.75% on a QoQ basis from $35.0 million in Q4 2025.
Innoviva (INVA) has 7 years of Receivables - Net data on file, last reported at $34.0 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Net rose 103.95% year-over-year to $34.0 million; the trailing twelve-month figure through Mar 2026 stood at $34.0 million (up 103.95% YoY), and the FY2025 full-year result was $35.0 million, up 71.47% from the prior year.
- Receivables - Net for Q1 2026 stood at $34.0 million, down from $35.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $35.0 million in Q4 2025 and bottomed at $6.7 million in Q3 2022.
- The 5-year median for Receivables - Net is $16.7 million (2025), against an average of $20.0 million.
- The widest annual swing landed in 2024, when Receivables - Net soared 184.1%; it then dropped 21.87% in 2025.
- A 5-year view of Receivables - Net shows it stood at $9.4 million in 2022, then soared by 53.75% to $14.5 million in 2023, then soared by 41.08% to $20.4 million in 2024, then soared by 71.47% to $35.0 million in 2025, then dropped by 2.75% to $34.0 million in 2026.
- The last three Receivables - Net figures came in at $34.0 million (Q1 2026), $35.0 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.01 Mn |
| Mar 31, 2026 | 34.01 Mn |
| Dec 31, 2025 | 34.97 Mn |
| Dec 31, 2025 | 34.97 Mn |
| Sep 30, 2025 | 30.17 Mn |
| Sep 30, 2025 | 30.17 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Mar 31, 2025 | 16.67 Mn |
| Mar 31, 2025 | 16.67 Mn |
| Dec 31, 2024 | 20.39 Mn |
| Dec 31, 2024 | 20.39 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 26.78 Mn |
| Jun 30, 2024 | 26.78 Mn |
| Mar 31, 2024 | 14.14 Mn |
| Mar 31, 2024 | 14.14 Mn |
| Dec 31, 2023 | 14.45 Mn |
| Dec 31, 2023 | 14.45 Mn |
| Sep 30, 2023 | 10.75 Mn |
| Sep 30, 2023 | 10.75 Mn |
| Jun 30, 2023 | 15.28 Mn |
| Jun 30, 2023 | 15.28 Mn |
| Mar 31, 2023 | 15.49 Mn |
| Mar 31, 2023 | 15.49 Mn |
| Dec 31, 2022 | 9.40 Mn |
| Dec 31, 2022 | 9.40 Mn |
| Sep 30, 2022 | 6.74 Mn |
| Sep 30, 2022 | 6.74 Mn |
| Mar 31, 2014 | 3,000.00 |
| Mar 31, 2014 | 3,000.00 |
| Dec 31, 2013 | 199,000.00 |
| Dec 31, 2013 | 199,000.00 |
| Sep 30, 2013 | 450,000.00 |
| Sep 30, 2013 | 450,000.00 |